Bempedoic Acid Side Effects: Gout, Tendon Risks, and What to Watch For

You’ve been told your cholesterol is too high. You tried statins, but the muscle pain was unbearable. So your doctor prescribes bempedoic acid, marketed as Nexletol or combined with ezetimibe as Nexlizet. It sounds like a miracle-a drug that lowers LDL cholesterol without the dreaded muscle aches. But it comes with its own set of trade-offs. While you might escape muscle pain, you could be walking into risks for gout attacks and tendon injuries.

Bempedoic acid isn’t just another pill; it’s a targeted therapy for people who can’t tolerate statins. Approved by the FDA in 2020, it works differently than traditional cholesterol drugs. However, understanding its side effect profile is crucial before you start taking it daily. This guide breaks down exactly what happens to your body, why these specific side effects occur, and how to manage them so you don’t end up in emergency care.

How Bempedoic Acid Works Differently Than Statins

To understand the side effects, you first need to know what the drug is doing inside you. Statins work by blocking an enzyme called HMG-CoA reductase in both your liver and your muscles. That’s why they cause muscle pain-they affect muscle tissue directly. Bempedoic acid is an ATP-citrate lyase inhibitor. Here’s the key difference: it only activates in the liver. Your muscles lack the enzyme needed to activate the drug, which is why it spares your muscles from the typical statin-induced myalgia (muscle pain).

This liver-specific action makes it a lifesaver for the 5-10% of patients who are statin-intolerant. It lowers LDL cholesterol by about 17-25%. But because it alters metabolic pathways in the liver, it shifts the burden elsewhere. Instead of muscle pain, you face issues related to uric acid buildup and connective tissue health. The CLEAR Outcomes trial published in the New England Journal of Medicine showed it reduces major cardiovascular events by 13%, proving it works. But efficacy doesn’t equal comfort, and the side effects require active management.

The Gout Connection: Why Your Joints Might Hurt

If you have ever experienced gout, you know it feels like someone is stabbing your big toe with ice picks. Bempedoic acid raises your risk for this condition significantly. Clinical data shows that approximately 1.5% of patients taking bempedoic acid experience gout attacks, compared to just 0.5% on placebo. More importantly, it causes hyperuricemia (high uric acid levels) in about 2.1% of users versus 0.4% in the control group.

Why does this happen? When bempedoic acid inhibits ATP-citrate lyase, it disrupts the production of citrate. Citrate normally helps the kidneys excrete uric acid. With less citrate available, uric acid stays in your blood longer. Eventually, it crystallizes in your joints, triggering inflammation. If you already have a history of gout, your risk jumps to 2.3% incidence during trials. Dr. Christopher Cannon from Harvard Medical School noted in JAMA Cardiology that clinicians must counsel patients on early signs of gout, such as sudden joint swelling or redness, typically appearing within the first four weeks of treatment.

Tendon Risks: The Silent Threat

While gout is painful and obvious, tendon injuries can be silent until they snap. Bempedoic acid carries a warning for tendonitis and tendon rupture. In clinical trials, tendon-related events occurred in 0.7% of patients taking the drug, compared to 0.1% in those taking a placebo. This might sound low, but tendons are critical for movement. A ruptured Achilles tendon requires surgery and months of rehabilitation.

The risk spikes dramatically if you combine bempedoic acid with other medications. GoodRx notes that when used alongside statins, the risk of tendon rupture is approximately 3.5 times higher than placebo. If you are also taking fluoroquinolone antibiotics (like Ciprofloxacin), the European Atherosclerosis Society advises avoiding bempedoic acid entirely due to additive toxicity. Symptoms to watch for include sudden pain in your heel, shoulder, or hand, hearing a 'pop' sound, or bruising around the tendon area. If you feel these symptoms, stop the medication and seek emergency care immediately. Do not wait to see if it gets better.

Common Side Effects: Spasms, Pain, and Fatigue

Not every side effect is life-threatening, but some are annoying enough to make you want to quit. Muscle spasms are the most common complaint, affecting about 5.8% of users compared to 2.5% on placebo. These aren’t the deep muscle aches of statins; they are more like charley horses in your calves or feet. Back pain (4.9%) and pain in the hands or feet (3.4%) are also frequently reported.

Other mild but frequent issues include:

• Upper respiratory infections: 7.7% of users report cold-like symptoms.
• Bronchitis: Occurs in 3.5% of patients.
• Fatigue: A general feeling of tiredness that often resolves after a few weeks.
• Abdominal pain: Mild stomach discomfort in 2.8% of cases.

Most of these side effects are transient. Healthline reports that muscle spasms often resolve within 2-4 weeks as your body adjusts. Only 1.2% of patients in trials discontinued the drug due to these milder symptoms. However, persistent pain should never be ignored. If back pain radiates down your leg or foot pain prevents walking, consult your doctor.

Serious Risks: Liver Enzymes and Anemia

Beyond joints and tendons, bempedoic acid affects internal organs. Elevated liver enzymes (ALT or AST) were seen in 2.2% of patients, compared to 0.9% on placebo. In 1.6% of cases, these levels exceeded three times the upper limit of normal. This doesn’t mean your liver is failing, but it signals stress. The FDA mandates regular monitoring of liver function tests (LFTs). Your doctor will likely check your baseline levels and then repeat them 4 weeks after starting, and every 3 months if levels remain elevated.

Anemia is another serious consideration. Bempedoic acid can reduce hemoglobin levels, leading to anemia in 1.8% of patients versus 0.5% on placebo. Dr. Christie Ballantyne from Baylor College of Medicine explained that these reductions are usually mild (less than 1 g/dL) and rarely require stopping the drug. However, if you already have chronic kidney disease or iron-deficiency anemia, this drop could be significant. Symptoms include extreme fatigue, pale skin, shortness of breath, and dizziness. Report these immediately.

Managing Side Effects: Practical Strategies

You don’t have to accept these risks passively. There are proven strategies to mitigate them. For gout prevention, Medical News Today cites data showing that prophylactic allopurinol (100-300 mg daily) reduces gout incidence by approximately 65% in bempedoic acid users. If you have high uric acid at baseline, ask your doctor about starting allopurinol before or when you begin bempedoic acid.

For tendon health, the American College of Rheumatology suggests implementing a gradual exercise program. Avoid sudden increases in intensity or impact activities like running or jumping during the first month of treatment. Stay hydrated, as dehydration worsens both gout and tendon stiffness. If you develop mild tendon pain, rest the affected area and apply ice. Do not push through sharp pain.

Regarding liver health, avoid alcohol excess and maintain a healthy weight. Obesity and fatty liver disease exacerbate enzyme elevations. Regular blood tests are non-negotiable. Do not skip your lab appointments. Early detection of rising uric acid or liver enzymes allows for dose adjustments or alternative therapies before permanent damage occurs.

When to Choose Alternatives

Bempedoic acid is powerful, but it isn’t for everyone. If you have a history of severe gout, uncontrolled hyperuricemia, or recent tendon surgery, discuss alternatives with your cardiologist. Ezetimibe alone lowers LDL by about 18-20% with a much lower risk of gout and tendon issues. PCSK9 inhibitors (like Repatha or Praluent) offer even greater LDL reduction (up to 60%) with minimal musculoskeletal side effects, though they require injections and carry higher costs.

The decision depends on your overall cardiovascular risk. If you have established atherosclerotic cardiovascular disease, the 13% reduction in major adverse events shown in the CLEAR Outcomes trial may outweigh the side effect risks. But if you are primary prevention with no prior heart attacks, the risk-benefit ratio changes. Always weigh the potential for gout flares against the certainty of plaque buildup in your arteries.